Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin‐like growth factor receptor in vitro and in an orthotopic model
Authors:
- 17 April 2007
- journal article
- Published by Wiley in Hepatology Research
- Vol. 37 (5) , 366-375
Abstract
Aim: The type I insulin‐like growth factor receptor (IGF‐IR) is overexpressed in many tumors including human hepatocellular carcinoma (HCC). It is a critical signaling molecule for tumor cell proliferation and survival. In the present study, IGF‐IR expression was down‐regulated by phosphorothioate antisense oligonucleotides (AS[S]ODN) to evaluate their specific effects on growth of hepatoma cells in vitro and in vivo. Methods: HepG2 cells were transfected with different doses of AS[S]ODN, sense [S]ODN, mismatch [S]ODN, or Lipofectin for 72 h, and cell proliferation was analyzed by MTS assay. In vivo, an orthotopic transplant model of HCC was established in nude mice, which were then injected with AS[S]ODN, sense [S]ODN, 5‐fluorouracil or saline. At the endpoint of treatment, the tumors were excised and evaluated. Results: Compared to sense and mismatched oligonucleotides, AS[S]ODN targeting to IGF‐IR mRNA significantly inhibited hepatoma cell lines HepG2 proliferation and IGF‐IR expression at both mRNA and protein levels. The in vivo results showed that systemic treatment also resulted in significant inhibition in tumor growth. Tumor growth in mice treated with AS[S]ODN (50 and 75 mg/kg per day) was significantly inhibited (71.81% and 61.74%, respectively) compared to the saline‐treated group (P < 0.01) in a dose‐dependent manner. The antitumor effect of IGF‐IR AS[S]ODN was associated with down‐regulation of IGF‐IR in tumor xenografts. Furthermore, IGF‐IR AS[S]ODN prevented liver recurrence tumor growth and metastasis in the lung, showing a dose‐dependent response. The level of serum α‐fetoprotein in AS[S]ODN‐treated groups was also decreased in a dose‐dependent manner, and a good correlation was observed between tumor volume and serum α‐fetoprotein concentration. Conclusions: These data suggest that IGF‐IR AS[S]ODN can effectively and specifically inhibit HCC growth in vitro and in vivo. Blockage of IGF‐IR expression could be a promising therapeutic approach for the management of patients with HCC.Keywords
This publication has 38 references indexed in Scilit:
- An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosisBiochemical Pharmacology, 2004
- The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapyGrowth Hormone & IGF Research, 2004
- Systemic therapy for advanced hepatocellular carcinoma: a reviewEuropean Journal of Cancer, 2004
- Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activityOncogene, 2004
- The Role of the IGF Axis in HepatocarcinogenesisHormone and Metabolic Research, 2003
- Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptorOncogene, 2003
- Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cellsJournal of Gastroenterology and Hepatology, 2003
- Insulin-like Growth Factor-I (IGF-I) Receptor Activation Rescues UV-damaged Cells through a p38 Signaling PathwayJournal of Biological Chemistry, 2001
- The IGF-I Receptor in Cancer ResearchExperimental Cell Research, 1999
- Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and AktMolecular and Cellular Biology, 1997